| Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. | |
| | |
MedLine Citation:
|
PMID: 15602727 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Eradication of chronic hepatitis C virus (HCV) infection depends upon a broad-based cellular immune response. Genetic immunization stimulates such a response, but the resultant activity is generally weak. Type 1 interferons (IFNs), which are known for their direct anti-viral and anti-proliferative properties, possess vigorous immunomodulatory properties. The aim of this study was to assess the capacity of IFN-alpha to augment the cellular immune response to DNA vaccination against HCV core protein. Three types of IFN-alpha were investigated: the non-species-specific hybrid IFN A/D, human pegylated IFN-alpha, and a plasmid that expressed murine IFN-alpha. Low doses of hIFN-A/D and hPegIFN-alpha augmented three to fourfold the cellular immune response to DNA-based vaccination, determined in conventional CTL assays, as well as in an in vivo tumor challenge model. Importantly, augmentation occurred within a narrow concentration range; a further increase in IFN dosage suppressed the CTL response significantly. Humoral immunity showed a very similar pattern of augmentation. These findings demonstrate that the immunomodulatory properties of IFN-alpha can be exploited to augment DNA based immunization, but it is important to consider the effects of dose on both cellular and humoral immune response for optimal augmentation. |
| | |
Authors:
|
Stephan Gehring; Stephen H Gregory; Noriyoshi Kuzushita; Jack R Wands |
Related Documents
:
|
9639327 - Culture of human amniotic cells: a system to study interferon production. 6092017 - Efficient constitutive production of human fibroblast interferon by hamster cells trans... 17281557 - Nitric oxide participates in the negative inotropic effect of interferon-alpha in rat c... 20926697 - Simultaneous measurement of antigen-stimulated interleukin-1 beta and gamma interferon ... 12759457 - Regulation of lipopolysaccharide sensitivity by ifn regulatory factor-2. 15140057 - Mercuric chloride induces a strong immune activation, but does not accelerate the devel... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Journal of medical virology Volume: 75 ISSN: 0146-6615 ISO Abbreviation: J. Med. Virol. Publication Date: 2005 Feb |
Date Detail:
|
Created Date: 2004-12-21 Completed Date: 2005-01-31 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 7705876 Medline TA: J Med Virol Country: United States |
Other Details:
|
Languages: eng Pagination: 249-57 Citation Subset: IM |
Affiliation:
|
The Liver Research Center, Rhode Island Hospital and Brown Medical School, Providence, Rhode Island 02903, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals CD8-Positive T-Lymphocytes / immunology Cytotoxicity, Immunologic Female Hepatitis C / immunology* Interferon Alfa-2a / administration & dosage, immunology* Interferon Type I, Recombinant / administration & dosage, immunology* Killer Cells, Natural / immunology Mice Mice, Inbred BALB C Polyethylene Glycols / administration & dosage T-Lymphocytes, Cytotoxic / immunology Time Factors Vaccines, DNA / immunology Viral Core Proteins / immunology* Viral Hepatitis Vaccines / administration & dosage, immunology* |
| Grant Support | |
ID/Acronym/Agency:
|
AA-20169/AA/NIAAA NIH HHS; AA-20666/AA/NIAAA NIH HHS; CA-35711/CA/NCI NIH HHS; P20RR 15578/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Interferon Type I, Recombinant; 0/Polyethylene Glycols; 0/Vaccines, DNA; 0/Viral Core Proteins; 0/Viral Hepatitis Vaccines; 0/peginterferon alfa-2a; 76543-88-9/Interferon Alfa-2a |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay ...
Next Document: Experimental norovirus infections in non-human primates.